c-MYC partners with BPTF in human cancer.
The c-MYC oncogene is deregulated in virtually all human tumors and therefore constitutes an attractive therapeutic target. We found that the chromatin remodeler BPTF is a c-MYC interactor required for c-MYC chromatin recruitment and transcriptional activity. Moreover, inhibition of BPTF delays tumor development both in vitro and in vivo and its levels positively correlate with c-MYC signatures in human tumors. We propose BPTF as a therapeutic target in c-MYC-addicted tumors.
Epithelial Carcinogenesis Group, Cancer Cell Biology Program, Spanish National Cancer Research Center-CNIO , Madrid, Spain.
Laia
L
Richart
Epithelial Carcinogenesis Group, Cancer Cell Biology Program, Spanish National Cancer Research Center-CNIO, Madrid, Spain; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
Francisco X
FX
Real
Epithelial Carcinogenesis Group, Cancer Cell Biology Program, Spanish National Cancer Research Center-CNIO , Madrid, Spain.
Victor Javier
VJ
Sanchez-Arevalo Lobo
BPTF; c-MYC; chromatin remodeling; transcription